GlassScriptPhysician profile
John J Volpi
NPI 1346443843
$406,669.39
in general payments reported to CMS, 2019-2025
43 companies · $8,688 in 2025
The $8,688 reported for 2025 was more than what 91% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112K · 2020: $66K · 2021: $49K · 2022: $72K · 2023: $42K · 2024: $56K · 2025: $8,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Consulting Fee: $27K · Travel and Lodging: $18K · Food and Beverage: $4,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,925.00 |
| Consulting Fee | $26,800.00 |
| Travel and Lodging | $18,230.18 |
| Food and Beverage | $4,011.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $193,464.50 | 2019-2024 | Xarelto |
| Amgen INC. | $84,477.75 | 2019-2025 | Repatha, Repatha |
| W. L. Gore & Associates, INC. | $76,613.34 | 2019-2025 | Gore Cardioform Septal Occluder, Product In Development, Gore Helex Septal Occluder |
| Portola Pharmaceuticals, LLC | $20,862.18 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $13,117.30 | 2024 | Magnetom Terra |
| Regeneron Pharmaceuticals, INC. | $7,370.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,743.30 | 2024-2025 | |
| Medtronic, INC. | $2,625.00 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $607.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $572.44 | 2021-2024 | Andexxa |
| Medtronic Vascular, INC. | $558.26 | 2019-2020 | |
| Abbott Laboratories | $523.95 | 2019-2022 | |
| Ucb, INC. | $458.84 | 2019-2025 | Briviact |
| Neurasignal INC. | $450.00 | 2024 | |
| Pfizer INC. | $303.03 | 2019-2025 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Volpi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.